GlassScriptPhysician profile
Despina Moise
NPI 1588968556
$2,073.94
in general payments reported to CMS, 2019-2025
18 companies · $512 in 2025
The $512 reported for 2025 was more than what 76% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.60 · 2020: $216 · 2021: $245 · 2022: $87.31 · 2023: $312 · 2024: $605 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,428.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $779.04 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $186.49 | 2020-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $183.18 | 2020-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $149.63 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $136.87 | 2020-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $111.72 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $107.79 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $101.48 | 2021-2024 | Qelbree |
| Allergan, INC. | $67.80 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $64.06 | 2020-2024 | Spravato |
| Corium, LLC | $53.43 | 2023 | Azstarys |
| Axsome Therapeutics, INC. | $22.77 | 2025 | Auvelity |
| Tris Pharma INC | $20.49 | 2023 | Dyanavel Xr |
| Noven Therapeutics, LLC | $19.90 | 2020 | |
| Neos Therapeutics, LP | $19.85 | 2024 | Adzenys Xr-Odt |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $17.94 | 2019 | |
| Ironshore Pharmaceuticals INC. | $17.66 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Despina Moise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.